cidofovir anhydrous has been researched along with Shingles in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (14.29) | 18.2507 |
2000's | 3 (42.86) | 29.6817 |
2010's | 3 (42.86) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Allouchi, H; Andrei, G; De Clercq, E; Enguehard-Gueiffier, C; Gueiffier, A; Snoeck, R; Véron, JB | 1 |
Alaibac, M; Peserico, A; Piaserico, S; Sandini, E | 1 |
Edelmann, A; Hofmann, J; Kühl, JS; Sauerbrei, A; Voigt, S | 1 |
Beer, M; Eyrich, M; Gattenlöhner, S; Girschick, HJ; Liese, J; Schick, J; Schlegel, PG; Weissbrich, B; Wiegering, V | 1 |
Lajusticia, J; Ramos, C | 1 |
Goh, CL; Tan, HH | 1 |
Gümbel, HO; Rockstroh, JK; Schliefer, K; Spengler, U | 1 |
2 review(s) available for cidofovir anhydrous and Shingles
Article | Year |
---|---|
Cutaneous viral infections in organ transplant patients.
Topics: Acitretin; Administration, Cutaneous; Aminoquinolines; Antiviral Agents; Cidofovir; Cytosine; Dermatologic Agents; Hair Diseases; Herpes Simplex; Herpes Zoster; Humans; Ichthyosis; Imiquimod; Immunocompromised Host; Immunosuppressive Agents; Incidence; Italy; Molluscum Contagiosum; Organ Transplantation; Organophosphonates; Skin Diseases, Viral; Transplant Recipients; Warts | 2014 |
Viral infections affecting the skin in organ transplant recipients: epidemiology and current management strategies.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Drug Administration Schedule; Epstein-Barr Virus Infections; Famciclovir; Foscarnet; Herpes Zoster; Herpesviridae Infections; Humans; Immunocompromised Host; Molluscum Contagiosum; Organ Transplantation; Organophosphonates; Papillomavirus Infections; Skin Diseases, Viral; Trifluridine; Valacyclovir; Valine | 2006 |
5 other study(ies) available for cidofovir anhydrous and Shingles
Article | Year |
---|---|
Influence of 6- or 8-substitution on the antiviral activity of 3-arylalkylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (CMV) and varicella-zoster virus (VZV): part II.
Topics: Antiviral Agents; Cell Survival; Cells, Cultured; Cytomegalovirus; Cytomegalovirus Infections; Herpes Zoster; Herpesvirus 3, Human; Humans; Imidazoles; Lung; Molecular Structure; Pyridines; Structure-Activity Relationship | 2008 |
Brincidofovir clearance of acyclovir-resistant herpes simplex virus-1 and adenovirus infection after stem cell transplantation.
Topics: Acyclovir; Adenoviridae; Adenovirus Infections, Human; Antibiotic Prophylaxis; Antiviral Agents; Child, Preschool; Cidofovir; Cytosine; DNA, Viral; Drug Resistance, Viral; Epstein-Barr Virus Infections; Female; Foscarnet; Hematopoietic Stem Cell Transplantation; Herpes Simplex; Herpes Zoster; Herpesvirus 1, Human; Herpesvirus 3, Human; Herpesvirus 4, Human; Humans; Immunocompromised Host; Meningoencephalitis; Mucositis; Myelodysplastic Syndromes; Organophosphonates; Rituximab; Viral Load | 2016 |
Varicella-zoster virus infections in immunocompromised patients - a single centre 6-years analysis.
Topics: Acyclovir; Antiviral Agents; Chickenpox; Child; Child, Preschool; Cidofovir; Cytosine; Female; Herpes Zoster; Herpesvirus 3, Human; Hospitalization; Humans; Immunocompromised Host; Incidence; Infant; Male; Organophosphonates; Practice Guidelines as Topic | 2011 |
[Infection due to acyclovir-resistant varicella-zoster herpes virus in a patient with AIDS].
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Cidofovir; Cytosine; Drug Resistance, Viral; Fatal Outcome; Female; Foscarnet; Herpes Zoster; Herpes Zoster Ophthalmicus; Herpesvirus 3, Human; Humans; Organophosphonates | 2004 |
Management of progressive outer retinal necrosis with cidofovir in a human immunodeficiency virus-infected patient.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytosine; Herpes Zoster; Humans; Injections, Intravenous; Male; Organophosphonates; Organophosphorus Compounds; Retinal Necrosis Syndrome, Acute; Severity of Illness Index; Treatment Outcome | 1999 |